Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer
Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.
Related Articles
Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC
Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.
Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL
Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML
Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC
Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.
Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care
Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.
Dr Flora on the Implications of Emerging AI Models for Oncology Care
Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.
Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’
Reshma Lillaney Mahtani, DO, highlights her experience as a leader in oncology and emphasizes the need to further uplift other women in the field.
MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD
Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.
Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025
Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024
Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.